Px Wire October-December 2016, Vol. 9, No. 4

The theme of this year’s World AIDS Day captures the spirit: Hands Up for HIV Prevention. At AVAC, we’re delighted to see the focus on this critical area of the global response. Our new issue of Px Wire provides specifics on some hot topics for advocacy before, on and after World AIDS Day.

HIV Prevention Research & Development Investments, 2000–2015: Investment priorities to fund innovation in a challenging global health landscape

This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2015, reported funding for HIV prevention R&D decreased from US$ 1.25 billion in 2014 to US$1.20 billion. However, overall funding has remained essentially flat for over a decade. While investments towards research for preventive vaccines and female condoms increased from 2014 levels, investments towards microbicides, PrEP, TasP, VMMC and PMTCT declined.

HIV Prevention Research & Development Investments, 2000–2015: Investment priorities to fund innovation in a challenging global health landscape (1-pager)

This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2015, reported funding for HIV prevention R&D decreased from US$ 1.25 billion in 2014 to US$1.20 billion. However, overall funding has remained essentially flat for over a decade. While investments towards research for preventive vaccines and female condoms increased from 2014 levels, investments towards microbicides, PrEP, TasP, VMMC and PMTCT declined.

Slow and Steady Won’t Win the Prevention Race

Progress in voluntary medical male circumcision has made significant gains but still fell short of targets—or why VMMC isn’t a global priority and how to make it one. Excerpted from AVAC Report 2016: Big Data, Real People.

PrEP for MSM in Africa: Meeting Summary and Next Steps

Advocates gather in South Africa for the continent’s first PrEP and MSM consultation to chart a path for PrEP access. See the report summary with links to presentations and country plans.

Programs but Not Yet Platforms: The peril and promise of women’s biomedical HIV prevention in 2016

The benefits of PrEP is winning over support from international bodies and an increasing number of national governments. PrEP introduction is advancing on several fronts, but all this momentum has yet to impact some of the people who need it most, in particular, adolescent girls and young women with high risk of acquiring HIV. Check out our up-close look at the issue from AVAC 2016’s Big Data, Real People.

New Analysis on Hormonal Contraception and HIV: WHO and others must act

An update excerpted from AVAC Report 2016: Big Data, Real People.

Px Wire July-September 2016, Vol. 9, No. 3

The International AIDS Conference in Durban was a reminder of how important the meeting can be in framing global issues and priorities. This issue of Px Wire offers a look at how the Durban wrap-up catapults us into the future.

The centerspread graphic features a scorecard for the conference (did it deliver?) and a novel look at how to use today’s tools to break the cycle of heterosexual transmission that was so clearly defined in a major Durban presentation.

State of the Funding in 2015

In 2015, preliminary reported funding for HIV prevention R&D decreased from US$ 1.25 billion in 2014 to US$1.18 billion. However, overall funding has remained essentially flat for over a decade. While investments towards research for preventive vaccines and female condoms increased from 2014 levels, investments towards microbicides, PrEP, TasP, VMMC, declined. Prevention of vertical transmission remained almost flat-funded in 2015.

The US public sector remained the single largest source of funding for HIV prevention R&D, with a total investment of US$836 million. European public sector investment continued its decade-long decline, falling US$8 million from 2014. Public sector funding outside the US and Europe also continued to fall, decreasing another US$5 million in 2015 for a total US$18 million decline since 2013. Finally, the philanthropic sector comprised 13% of all funding at US$155 million, a 23 percent decrease from 2014 contributions, while the commercial sector increased its contribution to HIV prevention R&D by 19 percent over 2014.

AVAC Report 2016: Big Data, Real People

In the Report, we argue that the state of HIV prevention data collection in 2016 is poor. One part of the solution lies in the adoption of “HIV Prevention Data Dashboards”. This tracking tool could bring the same specificity and accountability to non-ART prevention services that the “treatment cascade” of diagnosis, initiation, retention and virologic suppression does for antiretrovirals for people living with HIV.